An official website of the United States government
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Wells G, Coyle D, Cameron C, et al. Safety, Effectiveness, and Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2012 Apr 9.
| OVERVIEW | |
|---|---|
| Interface: | OVID |
| Databases: | • Medline (In-Process & Other Non-indexed Citations and OVID Medline (1948 to Dec 2, 2011); • Embase Classic and Embase (1947 to Dec 02, 2011) • Wiley Cochrane Database for Systematic Reviews • DARE (Database of Reviews of Effectiveness) |
| Date of Search: | December 2, 2011 |
| Study Types: | Randomized controlled trials, non-randomized studies |
| Limits: | • English language |
| SYNTAX GUIDE | |
| / | At the end of a phrase, searches the phrase as a subject heading |
| .sh | At the end of a phrase, searches the phrase as a subject heading |
| fs | Floating subheading |
| exp | Explode a subject heading |
| $ | Truncation symbol, or wildcard: retrieves plural or variations of a word |
| * | Indicates that the marked subject heading is a primary topic |
| ? | Truncation symbol for one or no characters only |
| ADJ | Requires words are adjacent to each other (in any order) |
| .ti | Title |
| .ab | Abstract |
| .hw | Heading Word; usually includes subject headings and controlled vocabulary |
| .pt | Publication Type |
| .rn | CAS registry number |
| MEDLINE Search Strategy |
|---|
| 1. (review or review, tutorial or review, academic).pt. |
| 2. (medline or medlars or embase or pubmed or cochrane).tw,sh. |
| 3. (scisearch or psychinfo or psycinfo).tw,sh. |
| 4. (psychlit or psyclit).tw,sh. |
| 5. cinahl.tw,sh. |
| 6. ((hand adj2 search$) or (manual$ adj2 search$)).tw,sh. |
| 7. (electronic database$ or bibliographic database$ or computeri?ed database$ or online database$).tw,sh. |
| 8. (pooling or pooled or mantel haenszel).tw,sh. |
| 9. (peto or dersimonian or der simonian or fixed effect).tw,sh. |
| 10. (retraction of publication or retracted publication).pt. |
| 11. or/2-10 |
| 12. 1 and 11 |
| 13. meta-analysis.pt. |
| 14. meta-analysis.sh. |
| 15. (meta-analys$ or meta analys$ or metaanalys$).tw,sh. |
| 16. (systematic adj5 review$).tw,sh. |
| 17. (systematic adj5 overview$).tw,sh. |
| 18. (quantitativ$ adj5 review$).tw,sh. |
| 19. (quantitativ$ adj5 overview$).tw,sh. |
| 20. (quantitativ$ adj5 synthesis$).tw,sh. |
| 21. (methodologic$ adj5 review$).tw,sh. |
| 22. (methodologic$ adj5 overview$).tw,sh. |
| 23. (intergrative research review$ or research integration).tw. |
| 24. or/13-23 |
| 25. 12 or 24 |
| 26. "randomized controlled trial".pt. |
| 27. (random$ or placebo$ or single blind$ or double blind$ or triple blind$).ti,ab. |
| 28. (retraction of publication or retracted publication).pt. |
| 29. or/26-28 |
| 30. (animals not humans).sh. |
| 31. ((comment or editorial or meta-analysis or practice-guideline or review or letter or journal correspondence) not "randomized controlled trial").pt. |
| 32. (random sampl$ or random digit$ or random effect$ or random survey or random regression).ti,ab. not "randomized controlled trial".pt. |
| 33. 29 not (30 or 31 or 32) |
| 34. ((oral or direct) adj3 thrombin inhibitor$).ti,ab. |
| 35. ((factor$ or antifactor$) adj3 (Xa inhibitor$ or drug$)).ti,ab. |
| 36. (edoxaban or lixiana).ti,ab. |
| 37. DU176b.mp. |
| 38. 36 or 37 |
| 39. (apixaban or eliquis).ti,ab. |
| 40. BMS-562247-01.mp. |
| 41. (dabigatran or pradaxa or pradax or prazaxa).ti,ab. |
| 42. EC3-4-21-5.mp. |
| 43. (rivaroxaban or xarelto).ti,ab. |
| 44. BAY59-7939.mp. |
| 45. or/34-44 |
| 46. 45 and 25 |
| 47. 45 and 33 |
| 48. exp cohort studies/ |
| 49. cohort$.tw. |
| 50. controlled clinical trial.pt. |
| 51. epidemiologic methods/ |
| 52. limit 51 to yr=1966-1989 |
| 53. exp case-control studies/ |
| 54. (case$ and control$).tw. |
| 55. or/48-50,52-54 |
| 56. 45 and 55 |
| 57. (ae or si or to or co).fs. |
| 58. (safe or safety).ti,ab. |
| 59. side effect$.ti,ab. |
| 60. ((adverse or undesirable or harm$ or serious or toxic) adj3 (effect$ or reaction$ or event$ or outcome$)).ti,ab. |
| 61. exp product surveillance, postmarketing/ |
| 62. exp adverse drug reaction reporting systems/ |
| 63. exp clinical trials, phase iv/ |
| 64. exp poisoning/ |
| 65. exp substance-related disorders/ |
| 66. exp drug toxicity/ |
| 67. exp abnormalities, drug induced/ |
| 68. exp drug monitoring/ |
| 69. exp drug hypersensitivity/ |
| 70. (toxicity or complication$ or noxious or tolerability).ti,ab. |
| 71. exp Postoperative Complications/ |
| 72. exp Intraoperative Complications/ |
| 73. or/57-72 |
| 74. or/36-44 |
| 75. (73 and 74) not (56 or 46 or 47) |
| Embase Search Strategy |
| 1. exp review/ |
| 2. (literature adj3 review$).ti,ab. |
| 3. exp meta analysis/ |
| 4. exp "Systematic Review"/ |
| 5. or/1-4 |
| 6. (medline or medlars or embase or pubmed or cinahl or amed or psychlit or psyclit or psychinfo or psycinfo or scisearch or cochrane).ti,ab. |
| 7. RETRACTED ARTICLE/ |
| 8. 6 or 7 |
| 9. 5 and 8 |
| 10. (systematic$ adj2 (review$ or overview)).ti,ab. |
| 11. (meta?anal$ or meta anal$ or meta-anal$ or metaanal$ or metanaly$).ti,ab. |
| 12. 9 or 10 or 11 |
| 13. (random$ or placebo$ or single blind$ or double blind$ or triple blind$).ti,ab. |
| 14. RETRACTED ARTICLE/ |
| 15. or/13-14 |
| 16. (animal$ not human$).sh,hw. |
| 17. (book or conference paper or editorial or letter or review).pt. not exp randomized controlled trial/ |
| 18. (random sampl$ or random digit$ or random effect$ or random survey or random regression).ti,ab. not exp randomized controlled trial/ |
| 19. 15 not (16 or 17 or 18) |
| 20. exp heart atrium fibrillation/ |
| 21. ((atrial or atrium or auricular) adj3 (fibrillat$ or flutter$)).ti,ab. |
| 22. 20 or 21 |
| 23. exp dabigatran etexilate/ or exp dabigatran/ |
| 24. (dabigatran or pradaxa or pradax or prazaxa).ti,ab. |
| 25. exp rivaroxaban/ |
| 26. (rivaroxaban or xarelto).ti,ab. |
| 27. BAY59-7939.mp. |
| 28. exp edoxaban/ |
| 29. (edoxaban or lixiana).mp. |
| 30. DU176b.mp. |
| 31. exp apixaban/ |
| 32. (apixaban or eliquis).mp. |
| 33. BMS-562247-01.mp. |
| 34. ((factor adj3 Xa) or (Xa adj3 inhibitor$) or (FXa adj3 inhibitor$)).mp. |
| 35. exp thrombin inhibitor/ |
| 36. or/23-35 |
| 37. 36 and 12 |
| 38. 36 and 19 |
| 39. exp cohort analysis/ |
| 40. exp longitudinal study/ |
| 41. exp prospective study/ |
| 42. exp follow up/ |
| 43. cohort$.tw. |
| 44. or/39-43 |
| 45. 36 and 44 |
| 46. 45 not (37 or 38) |
| 47. (ae or si or to or co).fs. |
| 48. (safe or safety).ti,ab. |
| 49. side effect$.ti,ab. |
| 50. ((adverse or undesirable or harm$ or serious or toxic) adj3 (effect$ or reaction$ or event$ or outcome$)).ti,ab. |
| 51. exp adverse drug reaction/ |
| 52. exp drug toxicity/ |
| 53. exp intoxication/ |
| 54. exp drug safety/ |
| 55. exp drug monitoring/ |
| 56. exp drug hypersensitivity/ |
| 57. exp postmarketing surveillance/ |
| 58. exp drug surveillance program/ |
| 59. exp phase iv clinical trial/ |
| 60. (toxicity or complication$ or noxious or tolerability).ti,ab. |
| 61. exp postoperative complication/ |
| 62. exp Peroperative Complication/ |
| 63. or/47-62 |
| 64. 36 and 63 |
| 65. 64 not (37 or 38 or 45) |
| 66. 65 and 22 |
| 67. 46 and 22 |
| 68. or/23-33 |
| 69. 63 and 68 |
| 70. 69 not (37 or 38 or 45) |
| Wiley Cochrane Database of Systematic Reviews, Controlled Trials and Economic Analyses, DARE and Grey Literature |
| Broad search terms such as atrial fibrillation, anticoagulants, and the drug names dabigatran, rivaroxaban, edoxaban, and apixaban were used. |
Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
Your browsing activity is empty.
Activity recording is turned off.
See more...
